Microbiota
VIDEO: ‘Distinctive shift’ in gut microbiota after Rebyota treatment for C. difficile
CHICAGO — In a Healio video exclusive, Ken Blount, PhD, discusses successful restoration of gut microbiota and clonal engraftment as soon as 1 week after treatment with Rebyota in those with recurrent Clostridioides difficile infection.
C. difficile infection recurrence after FMT higher than previously reported in IBD
CHICAGO — More than 20% of patients with inflammatory bowel disease experienced recurrent Clostridioides difficile infection 1 year after fecal microbiota transplantation, according to data presented at Digestive Disease Week.
FDA approves Vowst as first oral microbiota biotherapeutic for recurrent C. difficile
The FDA has approved Vowst, the first orally administered fecal microbiota product indicated for the prevention of recurrent Clostridioides difficile infection in adults following antibacterial treatment.
Fecal transplants for babies born by cesarean section may contain harmful pathogens
More than 40% of healthy mothers recruited for a study testing fecal transplantation for babies born by cesarean section tested positive for potentially harmful pathogens, Finnish researchers reported.
Bezlotoxumab, fecal microbiota transplant similarly effective in preventing recurrent CDI
Bezlotoxumab and fecal microbiota transplantation were similarly effective at preventing both early and late recurrent Clostridioides difficile infection, according to a study published in Open Forum Infectious Diseases.
Airway microbiota ‘unlikely to be a strong target’ in severe childhood asthma/wheeze
Children with asthma/wheeze demonstrated a strong relationship between age and airway microbiota, with a modest difference observed based on asthma severity, according to study results published in Annals of the American Thoracic Society.
FMT not linked to weight loss outcomes in patients undergoing bariatric surgery
Fecal microbiota transplantation 6 months before bariatric surgery did not reduce body weight in a small cohort of patients with obesity in Finland, according to study results published in JAMA Network Open.
AGA ‘applauds FDA’ for first approved fecal microbiota biotherapeutic
Following FDA approval of the first fecal microbiota biotherapeutics for recurrent Clostridoides difficile, the American Gastroenterological Association summarized what this means for gastroenterologists and patients going forward.
FDA approves fecal microbiota biotherapeutic for recurrent C. difficile infection
The FDA has approved Rebyota, a microbiota-based live biotherapeutic indicated for the prevention of recurrent Clostridioides difficile infection in adults after antibiotic treatment, Ferring Pharmaceuticals announced in a press release.
Greater bacterial, fungal lung microbiota burden linked to nonresolving ARDS in COVID-19
A higher bacterial and fungal lung microbiota burden in patients with COVID-19 was linked to nonresolving acute respiratory distress syndrome, according to a study published in American Journal of Respiratory and Critical Care Medicine.